ASAbhalaxmi Singh

Abhalaxmi Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abhalaxmi Singh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polyplex of peptide-mannan and RNA for intranasal delivery of TGF-β siRNA in treatment of pulmonary fibrosis

    by Bailin Feng, Abhalaxmi Singh, Yiqing Yang, Philana Phan, Han Xu, Yuli Zhu, Jennifer Huang, Vrushank Sastry, Zongmin Zhao, Ying S. Hu, et al.

    Pulmonary fibrosis is a progressive, severe respiratory disease, often considered terminal, with a typical life expectancy of only a few years. It is marked by excessive deposition of extracellular matrix proteins, driven by a complex interplay of profibrotic signaling pathways, including contributions from monocyte-derived alveolar macrophages (Mo-AMs) and various immune and stromal cells. In this study, we present a peptide-mannan conjugate nanoparticle (PMNP) platform for the targeted delivery of transforming growth factor-β small interfering RNA (TGF-β siRNA) aimed at halting and reversing pulmonary fibrosis. The nanoparticles of TGF-β siRNA and peptide-mannan conjugates, generated through a solvent-free and easily scalable process, were administered intranasally to specifically target the alveolar macrophage population. In fibrotic models, these nanoparticles effectively reduced Mo-AM infiltration, reprogrammed the macrophage phenotype, and significantly reduced collagen deposition. Our findings suggest that intranasal delivery of TGF-β siRNA via PMNP offers a promising, easily self-assembled, and patient-friendly therapeutic approach for the treatment of lung fibrosis.

  • Open Access

    Targeting a specific subset of neutrophils to mitigate cardiac reperfusion injury

    by Abhalaxmi Singh, Andrew Stuart, Sreeparna Chakraborty, Asrar Malik, Kurt Bachmaier

    Ischemia reperfusion (IR)-induced oxidative stress and inflammation contribute to morbidity and mortality of acute coronary syndrome. Ischemia results in profound hypoxia and tissue dysfunction and subsequent reperfusion further aggravates ischemic cardiac tissue damage. In cardiac IR injury, neutrophils are involved both in causing cardiomyocyte death and in preserving heart tissue homeostasis. We tested the hypothesis that neutrophil subpopulations show distinct functions in the pathogenesis of cardiac IR injury and that their functional heterogeneity can be exploited in subset-specific pharmacological intervention to prevent IR-induced myocardial tissue damage and functional deterioration. Cardiac IR-injury in a mouse model was characterized by the presence of two distinct heart-inflammatory subsets of neutrophils, one that specifically endocytosed albumin nanoparticles (ANP high ) and one that endocytose few or no ANP (ANP low ). The two subsets had very distinct inflammatory phenotypes. ANP high neutrophils expressed significantly greater amounts of inflammatory mediators, such as Il-1b and Ccl3, than ANP low neutrophils. Targeting the Spleen tyrosine kinase (Syk) specifically in ANP high neutrophils post IR reduced cardiac neutrophilic and mononuclear inflammation and drastically decreased infarct size, and prevented the deterioration of cardiac function. Targeting the Syk pathway specifically in a defined subset of neutrophils is a feasible therapy for cardiac IR injury.